Tag: Obesity
Weight regain seems to occur within 2 years of stopping obesity drugs
Obesity is a prevalent health issue that affects millions of people worldwide. In the quest to combat obesity,…
Why the weight, and heart risks, return after stopping GLP-1 drugsStopping obesity drugs means people regain weight and lose heart health benefitsÂ
Elizabeth Cooney, a cardiovascular disease reporter at STAT, delves into the complex world of weight loss drugs and…
Employers drop obesity drug coverage as cash-pay programs grow
HCA Healthcare, one of the largest hospital systems in the United States, recently made the decision to stop…
World Health Organization Recommends GLP-1 Drugs Like Ozempic For Obesity. Here’s What To Know
Obesity is a global epidemic that affects over a billion people worldwide, leading to serious health conditions such…
There’s a Surprising Link Between a Key Nutrient, Obesity, And Alzheimer’s Risk : ScienceAlert
Obesity and Low Choline Levels Linked to Accelerated Brain Aging, Study Finds A recent study has shed light…
Trump’s Price Cuts For Obesity Drugs Raise More Questions Than Answers
President Trump recently announced that his administration has successfully negotiated lower prices for certain weight loss medications with…
Novo Nordisk trims outlook as obesity drug maker loses ground to Eli Lilly
Novo Nordisk, a leading pharmaceutical company known for its Wegovy obesity drug, has recently faced challenges in the…
Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid
Pfizer Files Lawsuit Against Metsera and Novo Nordisk Over Merger Agreement In a recent development, Pfizer has taken…
Metsera the US obesity biotech at centre of Novo, Pfizer bidding war
Metsera Emerges as the Hottest Contender in the Obesity Drug Market Metsera, a New York-based biotech company, has…
STAT+: Can food noise be measured? Telehealth giant Ro rolls out a new scale for obesity care
Telehealth companies capitalizing on the recent surge in weight loss medications are increasingly influential, not only in assisting…
Jim Cramer Highlights Eli Lilly’s Drug Potential Beyond Diabetes and Obesity
Eli Lilly and Company (NYSE: LLY) has been examined closely by Jim Cramer. He emphasized the significance of…
Child obesity is now more common than undernutrition – what do we do?
Rising Childhood Obesity: An Alarming Global Shift Ultra-processed foods might be responsible for a rise in obesity levels…